Accredited Wealth Management LLC Has $42,000 Stock Position in Gilead Sciences, Inc. $GILD

Accredited Wealth Management LLC lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 94.4% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 375 shares of the biopharmaceutical company’s stock after selling 6,344 shares during the period. Accredited Wealth Management LLC’s holdings in Gilead Sciences were worth $42,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Corundum Trust Company INC bought a new position in Gilead Sciences during the third quarter worth $26,000. Howard Hughes Medical Institute acquired a new position in Gilead Sciences in the 2nd quarter valued at approximately $30,000. MTM Investment Management LLC grew its holdings in shares of Gilead Sciences by 176.0% during the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 176 shares in the last quarter. Kilter Group LLC acquired a new stake in Gilead Sciences during the second quarter worth $33,000. Finally, Millstone Evans Group LLC raised its stake in shares of Gilead Sciences by 58.7% in the 3rd quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 118 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Up 3.6%

Shares of GILD stock opened at $148.95 on Friday. The firm’s fifty day moving average price is $136.10 and its two-hundred day moving average price is $124.81. The company has a current ratio of 1.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.98. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $157.29. The firm has a market capitalization of $184.91 billion, a P/E ratio of 22.00, a PEG ratio of 1.95 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.83 by $0.03. The business had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter last year, the firm posted $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Friday, March 13th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio (DPR) is 46.68%.

Insiders Place Their Bets

In related news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the completion of the sale, the director directly owned 8,920 shares of the company’s stock, valued at approximately $1,101,620. This represents a 35.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $154.43, for a total value of $463,290.00. Following the completion of the transaction, the chief financial officer owned 167,779 shares of the company’s stock, valued at $25,910,110.97. This trade represents a 1.76% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 299,280 shares of company stock valued at $42,487,570. Insiders own 0.27% of the company’s stock.

Analysts Set New Price Targets

GILD has been the subject of a number of recent analyst reports. Argus increased their target price on shares of Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. Needham & Company LLC restated a “buy” rating and set a $170.00 price target on shares of Gilead Sciences in a research report on Monday, February 23rd. Mizuho increased their target price on Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a report on Wednesday, February 18th. Royal Bank Of Canada lifted their price target on Gilead Sciences from $103.00 to $118.00 and gave the company a “sector perform” rating in a report on Wednesday, February 11th. Finally, HSBC upped their price target on shares of Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a research report on Wednesday, December 10th. Twenty-three analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $156.72.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead highlighted a twice-yearly HIV prevention injection with reported 99.9% efficacy (executive interview), reinforcing the company’s long-acting HIV/IP prevention market potential and upside to future sales if uptake and approvals follow. Johanna Mercier on Gilead’s HIV prevention innovation
• Positive Sentiment: New Phase 3 ARTISTRY-1 and ARTISTRY-2 data show the investigational single-tablet bictegravir/lenacapavir (BIC/LEN) maintained virological suppression when patients switched regimens — strengthens pipeline value and switch-market potential. Gilead’s Single-Tablet Regimen Maintained Virological Suppression
• Positive Sentiment: Daiwa raised its price target to $161 and kept an “outperform” rating, signaling buy-side confidence and giving shares technical/analyst momentum. Daiwa Securities Adjusts Price Target on Gilead Sciences
• Positive Sentiment: UBS reiterated a Buy with a $175 target, citing the advancing long-acting HIV franchise — another supportive analyst endorsement for upside. Gilead Sciences: Advancing Long-Acting HIV Franchise
• Positive Sentiment: Zacks issued a series of upward revisions to Gilead’s FY2026–FY2028 and multiple quarterly EPS forecasts (raises across 2026–2028), which supports higher medium-term earnings expectations. Zacks Research GILD Estimates
• Neutral Sentiment: Coverage pieces note Gilead has been outperforming the healthcare sector recently and analysts remain optimistic — supports momentum but is descriptive rather than new fundamental news. Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector?
• Neutral Sentiment: Industry/peer updates such as Kymera’s results were reported but are not directly material to Gilead’s near-term outlook. Kymera Therapeutics Q4 Highlights
• Negative Sentiment: Zacks trimmed its Q3 2026 EPS estimate slightly (from $2.34 to $2.30) — a small near-term downgrade within otherwise stronger multi-year raises; worth monitoring for quarterly variability. Zacks Lowers Q3 2026 Estimate
• Negative Sentiment: Merck reported promising Phase 3 results for a two-drug HIV regimen that matched Gilead’s Biktarvy, representing competitive pressure if approved. Investors should monitor regulatory outcomes and market-share implications. Merck’s New HIV Drug Shows Promise

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.